chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Zero antibodies on antibody test for COVID antibodies; This spontaneous case was reported by a consumer and describes the occurrence of ANTIBODY TEST NEGATIVE (Zero antibodies on antibody test for COVID antibodies) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Relapsing-remitting multiple sclerosis. Concomitant products included OCRELIZUMAB (OCREVUS) for an unknown indication.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced ANTIBODY TEST NEGATIVE (Zero antibodies on antibody test for COVID antibodies). At the time of the report, ANTIBODY TEST NEGATIVE (Zero antibodies on antibody test for COVID antibodies) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Antibody test: inconclusive (Inconclusive) Zero antibodies.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       concomitant medication are not provided. Treatment information does not provided.   Reporter did not allow further contact
Patient presented with possible allergic reaction described as feeling "tingles everywhere" and "weird taste" in mouth. The symptoms began about 15 minutes ago after receiving the Pfizer COVID vaccine dose #1  Patient was treated with Benadryl, Solu-medrol and NS 1L bolus. Symptoms improved. Normal lung sounds. No signs of further reaction
Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; This spontaneous case was reported by an other health care professional and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) in a 51-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 14-Feb-2021 at 4:24 PM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 14-Feb-2021 at 4:24 PM, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). In 2021, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Age of patient was reported as 51.72 for dose administered on 14-Feb-2021.  No concomitant medications were reported.  Batch number 031L20A underwent temperature excursion on 12-Feb-2021 with temperature 35 degrees Fahrenheit from 10:00 AM to 11:00 AM, on 13-Feb-2021 with temperature 32 degrees Fahrenheit at 09:00 AM and 14-Feb-2021 with temperature 32,35 degrees Fahrenheit from 09:00 AM to 03:00 PM. This vial was moved to fridge on 09-Feb-2021 and beyond use date for the vial was reported as 10-Mar-2021. Product moved to clinic on 13-Jan-2021 and 12-Feb-2021.  Vial was in cooler storage and was not in frozen storage during high-pace COVID-19 vaccination at around 2021. Vials were only punctured right before administration. Vaccines were not frozen at time of administration. It was reported that each time a vial was put into a cooler, sometimes there was a period of 1 hour or 1 hour and a half approximately, when temperature data logger registered a temperature of 34- or 35-degree Fahrenheit. Temperature recordings were taken using a Fisher brand traceable temperature monitor at every hour. No treatment medications were reported.   This case was linked to MOD-2022-566976 (Patient Link).
I have both inflammation in my left and right shoulder I noticed in my right shoulder that it started out with mild soreness to wear at this time it becomes unbearable with Information in the shoulder on my left arm I have a sharp pain in the shoulder door at sometimes it?s very unbearable these both happen after my Covid 19 shots.
Patient reports have nausea, Body aches and chilled on 6/10/21 and missing 2 days of work
With in 15 minutes my fingers on my left hand started going numb. I had the shot in my Right arm.  By the next morning I was numb from the neck down and my vision went in my left ye and very blurry in the right eye.
12/21/2021  Phone call to parent, that COVID test was positive.  No other information provided, such as symptoms.
After a couple days, patient noticed redness, swelling, warmness to touch, bruising at site. Roughly .50 cent piece size.
passed out; dizziness; feeling nauseos; fell; hitting his head; This case was reported by a other health professional and described the occurrence of passed out in a male patient who received HAV (Havrix) (batch number 299X2, expiry date unknown) for prophylaxis.   On an unknown date, the patient received Havrix. On an unknown date, less than 6 months after receiving Havrix, the patient experienced passed out (serious criteria GSK medically significant), dizziness, nausea, fall and head injury. On an unknown date, the outcome of the passed out, dizziness, nausea, fall and head injury were unknown.   It was unknown if the reporter considered the passed out, dizziness, nausea, fall and head injury to be related to Havrix.  Additional information was reported as follows: The age at vaccination was not reported. After vaccination, the patient experienced dizziness and feeling nauseous. The patient was stood up and passed out. The patient fell backwards hitting his head on floor. This accident occurred under circumstances for which super markets. The reporter requested that, GlaxoSmithKline (GSK) report this promptly to the insurer or arrange for proper investigation and disposition. Also requested that, GSK acknowledge receipt of this notice in writing within fifteen (15) days and advise the undersigned of the name and address of the insurer or other person to whom they might look for handling. This case has been linked with case US2019AMR172641, reported by the same reporter.
Relapse; This spontaneous case was reported by a consumer and describes the occurrence of CONDITION AGGRAVATED (Relapse) in a 35-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   In June 2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced CONDITION AGGRAVATED (Relapse) (seriousness criterion hospitalization). The patient was hospitalized for 7 days due to CONDITION AGGRAVATED. At the time of the report, CONDITION AGGRAVATED (Relapse) had resolved.            Concomitant medications were not provided by the reporter. Treatment information was not provided by the reporter. Limited information regarding the event has been provided at this time and is insufficient for causality assessment.   Most recent FOLLOW-UP information incorporated above includes: On 13-Jul-2021: Live follow up received on 13-JUL-2021, contains no new information.; Sender's Comments: Limited information regarding the event has been provided at this time and is insufficient for causality assessment.
Confirmed Positive for COVID; Confirmed Positive for COVID; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 50 year-old female patient received bnt162b2 (BNT162B2), administration date 07Oct2021 (Lot number: FF2540) at the age of 50 years as dose 3 (booster), single, administration date 18Feb2021 (Lot number: EL3247) as dose 2, single and administration date 28Jan2021 (Lot number: EL3247) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The patient received no other vaccine in four weeks, no other medications in two weeks. The patient had no covid prior vaccination. The patient was covid tested post vaccination. The patient had no known allergies and none other medical history. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset 20Mar2022, outcome "recovering" and all described as "Confirmed Positive for COVID". The patient underwent the following laboratory tests and procedures: sars-cov-2 test: (21Mar2022) positive, notes: Nasal Swab; (22Mar2022) positive, notes: Confirmed Positive for COVID via PCR test on 22Mar2022 at 6:25pm. Therapeutic measures were not taken as a result of vaccination failure, covid-19. The patient confirmed Positive for COVID via PCR test on 22Mar2022 at 6:25 PM.
HIVES RIGHT, LEFT LEG, BACK AND RIGHT CALF; This spontaneous report received from a patient concerned a female of unspecified age. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine (suspension for injection, route of admin not reported, batch number: 1805020 and expiry: UNKNOWN) dose was not reported, administered on 28-MAR-2021 17:00 vaccinated on left arm for prophylactic vaccination. No concomitant medications were reported.  On 30-MAR-2021, the subject experienced hives right, left leg, back and right calf. The action taken with covid-19 vaccine was not applicable. The patient had not recovered from hives right, left leg, back and right calf. This report was non-serious.
This spontaneous report was receivd from a 53 year old female patient, regarding herself. Patient's pertinent medical history was reported as none. Patient was reported as allergic to MAXIDE, WELLBUTRIN and penicillin. On 02-DEC-2014 the patient was vaccinated with ZOSTAVAX .65 ml, subcutaneous (lot #, expiry date unspecified). Concomitant medications included other unspecified medications (unspecified names, dose/frequencies and manufacturers). On 02-DEC-2014, patient experienced an itchy and red inflamed rash, at the injection site, after receiving ZOSTAVAX. No treatment was given for the adverse event. Outcome of the events were reprted as not recovered. No product quality complaint (PQC) was reported. Causality assessment was not provided. Additional information has been requested.
Patient reported blister a day after vaccination, with slight irrigation. Referred patient to see primary care or urgent care for further evaluation, patient reported symptoms to the pharmacy 06/03/2022. Will follow up with patient 06/06/2022.
Approximately a minute after receiving it I felt a wave of heat start at my feet and go to my head. I then felt my heart rate increase. I took my heart rate from my apple watch and it was 145. Spoke to the nurse on site and she took my BP which was 185/140 (I am normally 120/80). Within a few minutes the heart rate started to drop but I was taken to the ED to be monitored. remained slightly tachicardic, but it was much better and BP dropped but was still elevated upon release -
I received the Johnson and Johnson Covid-19 vaccine on 5/1/2021. Starting on 5/11/2021 I started to get acute joint pain and swelling of the hands and wrists. I went to the Dr. on 5/14/2021. He prescribed Benadryl and Pepcid AC taken together to lessen the swelling, pain and reaction.
Red, Swollen, and warm to the touch halfway down patient upper arm lasting 2 days. Limited loss of motion for 2 days which came back on 3rd day. Patient said arm feels normal now and no treatment was needed.
On the outset: There is no proven link of the vaccine with what happened, but I am filling this just in case you see a pattern emerge: She was vaccinated (pfizer, 1st dose) on Saturday, May 15 2021. A couple of hours later she started experiencing mild symptoms (moderate headache, which we thought as a normal reaction). These persisted on and off  until Wednesday, May 19th, when patient started having swollen and painful glands at the back of her mouth. Long story short, after testing first for strep, followed by blood work, patient's blood test came back positive with mono on Monday, May 24. The reason for this report is that I have read that mRNA vaccines, great as they may be, may trigger a virus response for viruses that stay within a person - like shingles or herpes etc. The way I understand it, mono also stays with a person. Patient had never been diagnosed with mono before, but mono sometimes does not have symptoms. So, is it possible that she had mono sometime before the vaccine, and it got re-triggered  due to the vaccine? Again, just in case you see a pattern, I am just reporting if helpful. Patient also developed  a mono rash on Wednesday, May 26; treated with topical benadryl cream.
No adverse event occured after giving vaccine, but the incorrect vaccine was given for the patient age. Patient should have received a pfizer brand covid vaccine, but instead received a Janssen vaccine at 11 years old.
Pt experienced redness at injection site and to the front of the arm with reduced range of motion. Arm was extremely sore to the touch and was still red three days later. Pt also experienced a low-grade fever on both sides of the head that did resolve with administration of ibuprofen.
I have sharp consistent migraines that worsened after the vaccination, a constant shooting pain like someone is drilling in my head.
Zostavax given R arm morning of 1/22/07.  Pt saw dermatologist that afternoon and was given effudex to treatment skin lesion on face and L chest.  Seen on 2/1/07 with 3 cm circular, varicella like rash on L chest including, but not limited to, area treated with Effudex.  No rash on face, no other areas of rash.  Effudex stoppped, no other treatment initiated. This is in follow-up to report (s) previously submitted on 3/14/2007. Information has been received from a physician and health professional concerning a 63 year old female with an allergy to sulfa who on 22-JAN-2007 at 09:00 AM was vaccinated SC in the right arem with a dose of VARIVAX (lot # 654603/1405F). There was no illness at the time of vaccination. Concomitant therapy included alendronate sodium (MSD) and QUESTRAN. Subsequently the patient developed a rash on the left side of her chest. The physician reported that in the afternoon on 22-JAN-2007, the patient saw a dermatologist who applied topical EFUDEX on an area of the chest to where the patient was vaccinated in the arm. It seemed like the rash apperared close to where the EFUDEX was applied. The dematologist also applied EFUDEX to two areas on the patient's face, but no rash occurred there. The physician thought hat the rash occurred soon after the cream was applied but was not sure. On 01-FEB-2007, the patient was examined by her physician. The physician could not confirm whether the rash resembled shingles or not. There was no product quality complaint involved. Additional information has been received from the physician who reported that the patient saw the dematologist in the afternoon of 22-JAN-2007 and was treated with EFUDEX to the face and left chest. In the afternoon of 01-FEB-2007, the patient had a 3 cm circular, varicella-like rash on the left chest including but not limited to, the area treated with EFUDEX. In follow-up on 06-FEB-2007, two new blisters had formed with some that were weepy, but the rash was drying and the patient had no pain. Subsequently, the patient recovered. No diagnostic tests were performed. The patient had no adverse events following prior vaccination. No further information is expected.
Patient received 2 Comirnaty vaccines instead of 1 Comirnaty and 1 Fluzone High Dose vaccine. No adverse events at this time
My arm was sore on the 1st day but about 6 or 7 days later my arm was swollen just below my shoulder down to my elbow  and today it is still swollen
WORSE COLDS; FEVER; This spontaneous report received from a patient via a company representative concerned a male of unspecified age. The patient's height, and weight were not reported. The patient's pre-existing medical conditions included: The patient was out of quarantine last week. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported. The company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported. On an unspecified date, the patient experienced worse colds, and fever. Laboratory data (dates unspecified) included: Body temperature (not provided) Maxing out at 102. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from worse colds, and fever. This report was non-serious. This report was associated with product complaint number 90000208328. This case, from the same reporter is linked to 20211250840.
"A physician reported that a 4 month old female received her first doses of Rota Shield, as well as Hibtiter,Acel Immune and IPV (Aventis Pasteur SA) vaccines on 12/01/98.On 12/03/98, the infant developed prolonged crying and "intense' abdominal cramping." from follow-up #1 correspondence received on 01/24/00, it was reported,"revised,no additional information at this time." Mailed follow - up #2 correspondence from 05/31/01 stated the patient recovered from this experience. No furhter information is anticipated for this report. Case is closed
Initially lt arm sore; later rt arm & upper legs very achy; no other sx; achiness persisted; 25NOV91 seen by MD; 27NOV91 seen by MD rx Pred x 5 days; by 2DEC91 improving;
(R) leg swollen, red with fever in leg. Tx with BENADRYL 12.5mg/5ml.
His psoriasis did flare up; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. Other Case identifier(s): NVSC2022US027548_NS.  A 32 year-old male patient received bnt162b2 (BNT162B2), administration date 2021 (Batch/Lot number: unknown) as dose number unknown (booster), single for covid-19 immunisation. Relevant medical history included: "Psoriasis" (ongoing). The patient's concomitant medications were not reported. The following information was reported: PSORIASIS (non-serious) with onset 27Dec2021, outcome "unknown", described as "His psoriasis did flare up".  Additional information: Patient advised when he received his COVID-19 booster shot his psoriasis did flare up. It was around 27Dec2021. Until that point his skin was clear but after he received the booster he did see his progress decline.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
arm soreness; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 68-year-old female patient received BNT162b2 (BNT162B2), in Apr2022 as dose 4 (booster), single (Batch/Lot number: unknown) at the age of 68 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Diverticulitis", start date: 2009 (ongoing), notes: Pulmonary Langerhans autoimmune of lungs and was on high risk. Oxygen levels 97% and she functions; "acid reflux" (unspecified if ongoing); "blood pressure" (unspecified if ongoing); "cholesterol" (unspecified if ongoing); "Pulmonary Langerhans" (unspecified if ongoing). Concomitant medication(s) included: LISINOPRIL taken for blood pressure measurement; TRAZODONE taken for sleep disorder; SIMVASTATIN taken for blood cholesterol; OMEPRAZOLE taken for gastrooesophageal reflux disease; PEPCID AC taken for gastrooesophageal reflux disease; B12 [CYANOCOBALAMIN] taken for supplementation therapy. Vaccination history included: BNT162b2 (Dose 1), administration date: 30Jan2021, for Covid-19 immunization, reaction(s): "did have something on her skin on her face under her eye near her cheek bone, she had what looked like a hive/ blister but it was red and it looked like it was raised", "Arm soreness"; BNT162b2 (Dose 1), administration date: 30Jan2021, for COVID-19 immunization, reaction(s): "did have something on her skin on her face under her eye near her cheek bone, she had what looked like a hive/ blister but it was red and it looked like it was raised"; BNT162b2 (Dose 1), administration date: 30Jan2021, for COVID-19 immunisation, reaction(s): "did have something on her skin on her face under her eye near her cheek bone, she had what looked like a hive/ blister but it was red and it looked like it was raised"; BNT162b2 (Dose 2), administration date: 20Feb2021, for Covid-19 immunization, reaction(s): "she got a hive on her face in a different spot on the same side of her face", "Arm soreness"; Bnt162b2 (DOSE 3 (BOOSTER), SINGLE), administration date: Sep2021, for Covid-19 immunization, reaction(s): "Arm soreness". The following information was reported: PAIN IN EXTREMITY (non-serious), outcome "unknown", described as "arm soreness". Relevant laboratory tests and procedures are available in the appropriate section.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Medical assistant calling to report a temperature excursion that occurred 8/14/2020 which involved the following products: GARDASIL9, PEDVAXHIB, RECOMBIVAX, ROTATEQ. Per caller, "it would be possible that at least 100 patients have received vaccines; This spontaneous report was received from a medical assistant, concerning a patient of unknown age and gender. The patient's pertinent medical history, concurrent conditions, drug reactions or allergies or concomitant medications were not reported.  On 27-AUG-2020, the patient was vaccinated with an improperly stored dose of rotavirus vaccine, live, oral, pentavalent (ROTATEQ) orally as prophylaxis (lot # 1660991 with expiration date 27-APR-2021) (strength, dose and frequency were not reported).  The improperly stored dose of rotavirus vaccine, live, oral, pentavalent (ROTATEQ) experienced a temperature excursion of 35.4 Fahrenheit degrees (°F) for the time frame of 20 minutes without previous temperature excursions. It was confirmed that a digital data logger was involved.  This is one of several cases from the same reporter.; Sender's Comments:  US-009507513-2009USA006106:
First cycle after giving birth 9/11/2020 happened a day before taking the vaccine. Once I received the vaccine, my cycle stopped completely. Also the lower back pins and wrist pains as a result of taking the epidural in 9/2020 which subsided 12/2020 came back the day after receiving   the vaccine.